Taysha Gene Therapies Files DEFA14A Proxy Materials
Ticker: TSHA · Form: DEFA14A · Filed: Apr 22, 2026 · CIK: 0001806310
Sentiment: neutral
Topics: proxy-filing, shareholder-materials, sec-filing
Related Tickers: TSHA
TL;DR
Taysha Gene Therapies (TSHA) filed proxy docs on 4/22/26. Shareholders, pay attention.
AI Summary
Taysha Gene Therapies, Inc. filed a DEFA14A on April 22, 2026, related to additional definitive proxy soliciting materials. The filing includes standard DEFA14A documents and graphic materials, with the company's mailing and business address listed as 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247.
Why It Matters
This filing indicates Taysha Gene Therapies is engaging in proxy solicitations, which are crucial for shareholder voting on corporate matters and executive compensation.
Risk Assessment
Risk Level: low — This is a routine filing for proxy materials and does not inherently indicate significant new risks for the company.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Filer of the DEFA14A
- 0001806310 (company) — CIK number for Taysha Gene Therapies, Inc.
- 2026-04-22 (date) — Filing date of the DEFA14A
- 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (location) — Mailing and business address of Taysha Gene Therapies, Inc.
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used for additional definitive proxy soliciting materials and Rule 14(a)(12) material, typically related to shareholder meetings and voting.
When was this DEFA14A filing accepted by the SEC?
The filing was accepted on 2026-04-22 at 08:02:49.
What is Taysha Gene Therapies, Inc.'s CIK number?
Taysha Gene Therapies, Inc.'s CIK number is 0001806310.
Where is Taysha Gene Therapies, Inc. located?
The company's mailing and business address is 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247.
What SIC code is associated with Taysha Gene Therapies, Inc.?
The SIC code is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 22, 2026 regarding Taysha Gene Therapies, Inc. (TSHA).